Advertisement

Double-masked, Randomized, Dose–Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure

Published:September 27, 2014DOI:https://doi.org/10.1016/j.ophtha.2014.08.022

      Objective

      AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine transporter. The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

      Design

      Double-masked, randomized study in 22 private practice ophthalmology clinics.

      Participants

      Participants were required to be adults with a diagnosis of OAG or OHT with unmedicated intraocular pressure (IOP) in the range of 22 to 36 mmHg.

      Methods

      Patients were randomized to receive AR-13324 ophthalmic solution 0.01%, daily (pm), AR-13324 ophthalmic solution 0.02% daily (pm), or latanoprost 0.005% daily (pm) for 28 days.

      Main Outcome Measures

      The primary efficacy endpoint was the mean diurnal IOP across subjects within the treatment group at day 28.

      Results

      Randomized and treated were 224 patients, 213 (95.1%) of whom completed the study. On day 28, mean diurnal IOP was 20.1, 20.0, and 18.7 mmHg in the AR-13324 0.01%, 0.02%, and latanoprost groups, respectively, representing a decrease from unmedicated baseline of 5.5, 5.7, and 6.8 mmHg (P<0.001). The 5.7-mmHg reduction in IOP by AR-13324 0.02% did not meet the criterion for noninferiority to latanoprost. The most frequently reported adverse event was conjunctival/ocular hyperemia, with a combined incidence of 52%, 57%, and 16%, respectively. On day 28 at 08:00 hours, the incidence of mild to moderate hyperemia by biomicroscopy was 18%, 24%, and 11%, respectively.

      Conclusions

      AR-13324 0.02% was less effective than latanoprost by approximately 1 mmHg in patients with unmedicated IOPs of 22 to 35 mmHg. The major safety finding was ocular hyperemia, which was more common for both concentrations of AR-13324 than for latanoprost.

      Abbreviations and Acronyms:

      IOP (intraocular pressure), mITT (modified intent to treat), OAG (open-angle glaucoma), OHT (ocular hypertension)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • AGIS Investigators
        The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.
        Am J Ophthalmol. 2000; 130: 429-440
        • Heijl A.
        • Leske M.C.
        • Bengtsson B.
        • et al.
        Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.
        Arch Ophthalmol. 2002; 120: 1268-1279
        • Kass M.A.
        • Heuer D.K.
        • Higginbotham E.J.
        • et al.
        Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
        Arch Ophthalmol. 2002; 120: 701-713
        • Lichter P.R.
        • Musch D.C.
        • Gillespie B.W.
        • et al.
        • CIGTS Study Group
        Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery.
        Ophthalmology. 2001; 108: 1943-1953
        • Toris C.B.
        • Gleason M.L.
        • Camras C.B.
        • Yablonski M.E.
        Effects of brimonidine on aqueous humor dynamics in human eyes.
        Arch Ophthalmol. 1995; 113: 1514-1517
        • Kass M.A.
        • Gordon M.O.
        • Gao F.
        • et al.
        Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: the Ocular Hypertension Treatment Study.
        Arch Ophthalmol. 2010; 128: 276-287
        • Janz N.K.
        • Wren P.A.
        • Lichter P.R.
        • et al.
        • CIGTS Study Group
        The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma.
        Ophthalmology. 2001; 108: 1954-1965
        • Brubaker R.F.
        Targeting outflow facility in glaucoma management.
        Survey Ophthalmol. 2003; 48: S17-20
        • Novack G.D.
        Rho kinase inhibitors for the treatment of glaucoma.
        Drugs Future. 2013; 38: 107-113
        • Williams R.D.
        • Novack G.D.
        • van Haarlem T.
        • Kopczynski C.
        AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
        Am J Ophthalmol. 2011; 152: 834-841
      1. Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes [report online]. J Glaucoma. Available at: www.journals.lww.com/glaucomajournal/Abstract/publishahead/Effect_of_0_04__AR_13324_a_ROCK,_and.99367.aspx. Accessed August 17, 2014.

        • Stone J.L.
        • Robin A.L.
        • Novack G.D.
        • et al.
        An objective evaluation of eye-drop instillation in glaucoma patients.
        Arch Ophthalmol. 2009; 127: 732-736
        • Sherwood M.B.
        • Craven E.R.
        • Chou C.
        • et al.
        Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
        Arch Ophthalmol. 2006; 124: 1230-1238
        • Hughes B.A.
        • Bacharach J.
        • Craven E.R.
        • et al.
        A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
        J Glaucoma. 2005; 14: 392-399
        • Hedman K.
        • Alm A.
        A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.
        Eur J Ophthalmol. 2000; 10: 95-104
        • Watabe H.
        • Abe S.
        • Yoshitomi T.
        Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.
        Jpn J Ophthalmol. 2011; 55: 411-417